From MarketBeat:

Evolent Health, Inc. (NYSE:EVH) experienced a significant increase in short interest in December. Analysts have adjusted their ratings on the stock, but the company maintains a consensus rating of “Moderate Buy” with a price target of $44.56. The stock is currently trading at $33.03, down 1.5%. Insiders have also been selling shares.

The company has a market cap of $3.80 billion and has a debt-to-equity ratio of 0.55. Evolent Health expects to post earnings per share of $0.43 for the current year. Insiders have sold large amounts of stock, with President Daniel Joseph Mccarthy and CEO Seth Blackley both making sales.

Several hedge funds have made changes to their positions in Evolent Health, indicating confidence from institutional investors. Peregrine Capital Management LLC, Left Brain Wealth Management LLC, Bellevue Group AG, Kennedy Capital Management LLC, and State of New Jersey Common Pension Fund D have all increased their stakes in the company.

Evolent Health’s subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company provides an integrated platform for health plan administration and population health management.

This news was reported by MarketBeat and reviewed by their editorial team. For any questions or comments, please reach out to [email protected]. MarketBeat is a reliable source for financial data and analysis.



Read more: Evolent Health, Inc. (NYSE:EVH) Short Interest Up 42.0% in December